Literature DB >> 23483520

Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND.

Thep Chalermchai1, Victor Valcour, Pasiri Sithinamsuwan, Suteeraporn Pinyakorn, David Clifford, Robert H Paul, Somporn Tipsuk, James L K Fletcher, Victor Degruttola, Silvia Ratto-Kim, Nicholas Hutchings, Cecilia Shikuma, Jintanat Ananworanich.   

Abstract

Although HIV-associated dementia (HAD) occurs in less than 5 % of individuals with access to combination antiretroviral therapy, rates of milder forms of HIV-associated neurocognitive disorder (HAND) are much higher. We sought to define an optimal cut point for the International HIV Dementia Scale (IHDS) in Thailand for the identification of symptomatic HAND, defined as both HAD and mild neurocognitive disorder. We then sought to determine if adding a simple test from a larger neuropsychological battery could improve the performance characteristics for identifying symptomatic HAND. In this study, subjects comprising 75 seropositive adults in Bangkok, Thailand, completed neuropsychological tests and underwent a full neurological assessment. HAND diagnoses were determined by consensus conference using the 2007 Frascati criteria, blinded to the IHDS results. The optimal IHDS cut point was determined by receiver operating characteristic analysis with cross-validation. Individual neuropsychological tests were then evaluated and combined with the IHDS to test performance characteristics. The IHDS was poor at detecting symptomatic HAND at the optimized cut point of ≤ 10 (sensitivity, 53.3 %; specificity, 89.8 %). Trail Making Test A was most effective in improving performance characteristics when combined with the IHDS, with net sensitivity of 86 % and specificity of 79 %. In this setting, the IHDS performed poorly in identifying symptomatic HAND, but was substantially improved by the addition of Trail Making Test A, which typically requires less than 2 min to complete. This combination should be validated in a larger setting since it may address the critical need for HAND screening instruments in international settings.

Entities:  

Mesh:

Year:  2013        PMID: 23483520      PMCID: PMC3644005          DOI: 10.1007/s13365-013-0151-4

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  42 in total

Review 1.  Cultural values underlying psychometric cognitive testing.

Authors:  Alfredo Ardila
Journal:  Neuropsychol Rev       Date:  2005-12       Impact factor: 7.444

2.  Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study.

Authors:  Mona A Mohamed; Peter B Barker; Richard L Skolasky; Ola A Selnes; Richard T Moxley; Martin G Pomper; Ned C Sacktor
Journal:  Magn Reson Imaging       Date:  2010-08-04       Impact factor: 2.546

3.  An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China.

Authors:  Yulin Zhang; Luxin Qiao; Wei Ding; Feili Wei; Qingxia Zhao; Xicheng Wang; Ying Shi; Ning Li; Davey Smith; Dexi Chen
Journal:  J Neurovirol       Date:  2012-03-13       Impact factor: 2.643

4.  Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death.

Authors:  N C Sacktor; H Bacellar; D R Hoover; T E Nance-Sproson; O A Selnes; E N Miller; G J Dal Pan; C Kleeberger; A Brown; A Saah; J C McArthur
Journal:  J Neurovirol       Date:  1996-12       Impact factor: 2.643

5.  Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder.

Authors:  Nishiena S Gandhi; Richard T Moxley; Jason Creighton; Heidi Vornbrock Roosa; Richard L Skolasky; Ola A Selnes; Justin McArthur; Ned Sacktor
Journal:  HIV Ther       Date:  2010-05

6.  Self-reported awareness of performance in dementia.

Authors:  David P Graham; Mark E Kunik; Rachelle Doody; A Lynn Snow
Journal:  Brain Res Cogn Brain Res       Date:  2005-09

7.  The International HIV Dementia Scale is a useful screening tool for HIV-associated dementia/cognitive impairment in HIV-infected adults in Yaoundé-Cameroon.

Authors:  Alfred K Njamnshi; Vincent de Paul Djientcheu; Julius Y Fonsah; Faustin N Yepnjio; Dora M Njamnshi; Walinjom E Muna
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-01       Impact factor: 3.731

8.  The HIV Dementia Scale: predictive power in mild dementia and HAART.

Authors:  Kara Anne Bottiggi; Jason J Chang; Frederick A Schmitt; Malcolm J Avison; Yunanan Mootoor; Avindra Nath; Joseph R Berger
Journal:  J Neurol Sci       Date:  2007-05-04       Impact factor: 3.181

9.  HIV-associated neurocognitive disorders (HAND) in a South Asian population - contextual application of the 2007 criteria.

Authors:  Lai Gwen Chan; Nagaendran Kandiah; Arlene Chua
Journal:  BMJ Open       Date:  2012-02-13       Impact factor: 2.692

10.  Nonopportunistic neurologic manifestations of the human immunodeficiency virus: an Indian study.

Authors:  Alaka K Deshpande; Mrinal M Patnaik
Journal:  J Int AIDS Soc       Date:  2005-10-04       Impact factor: 5.396

View more
  9 in total

1.  Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study.

Authors:  Angela Matinella; M Lanzafame; M A Bonometti; A Gajofatto; E Concia; S Vento; S Monaco; S Ferrari
Journal:  J Neurol       Date:  2015-04-01       Impact factor: 4.849

2.  Diagnostic Utility of the International HIV Dementia Scale for HIV-Associated Neurocognitive Impairment and Disorder in South Africa.

Authors:  Karl Goodkin; David J Hardy; Dinesh Singh; Enrique Lopez
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2014       Impact factor: 2.198

3.  Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection.

Authors:  Louise Leyre; Eugène Kroon; Claire Vandergeeten; Carlo Sacdalan; Donn J Colby; Supranee Buranapraditkun; Alexandra Schuetz; Nitiya Chomchey; Mark de Souza; Wendy Bakeman; Rémi Fromentin; Suteeraporn Pinyakorn; Siriwat Akapirat; Rapee Trichavaroj; Suthat Chottanapund; Sopark Manasnayakorn; Rungsun Rerknimitr; Phandee Wattanaboonyoungcharoen; Jerome H Kim; Sodsai Tovanabutra; Timothy W Schacker; Robert O'Connell; Victor G Valcour; Praphan Phanuphak; Merlin L Robb; Nelson Michael; Lydie Trautmann; Nittaya Phanuphak; Jintanat Ananworanich; Nicolas Chomont
Journal:  Sci Transl Med       Date:  2020-03-04       Impact factor: 17.956

Review 4.  HIV-associated neurocognitive disorder.

Authors:  David B Clifford; Beau M Ances
Journal:  Lancet Infect Dis       Date:  2013-11       Impact factor: 25.071

Review 5.  Neurology and the Global HIV Epidemic.

Authors:  Ana-Claire Meyer
Journal:  Semin Neurol       Date:  2014-04-08       Impact factor: 3.420

6.  Lifetime suicide attempt history, quality of life, and objective functioning among HIV/AIDS patients with alcohol and illicit substance use disorders.

Authors:  Kimberly N Walter; Nancy M Petry
Journal:  Int J STD AIDS       Date:  2015-05-06       Impact factor: 1.359

Review 7.  Screening for HIV-Associated Neurocognitive Disorders: Sensitivity and Specificity.

Authors:  Reuben N Robbins; Travis M Scott; Hetta Gouse; Thomas D Marcotte; Sean B Rourke
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 8.  Validity of cognitive screens for HIV-associated neurocognitive disorder: a systematic review and an informed screen selection guide.

Authors:  Jody Kamminga; Lucette A Cysique; Grace Lu; Jennifer Batchelor; Bruce J Brew
Journal:  Curr HIV/AIDS Rep       Date:  2013-12       Impact factor: 5.071

9.  Psycho-behavioral factors associated with neurocognitive performance among people living with HIV on antiretroviral therapy in Accra, Ghana.

Authors:  Nana Asiedu; Irene Kretchy; Emmanuel Asampong
Journal:  Afr Health Sci       Date:  2020-06       Impact factor: 0.927

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.